Breakdown | ||||
Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
764.81B | 736.56B | 692.16B | 611.63B | 550.34B | Gross Profit |
275.30B | 261.01B | 239.83B | 216.07B | 185.80B | EBIT |
131.22B | 120.41B | 111.83B | 106.22B | 80.75B | EBITDA |
187.97B | 171.26B | 154.67B | 144.60B | 123.82B | Net Income Common Stockholders |
93.76B | 79.64B | 76.31B | 71.44B | 52.87B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
168.60B | 173.94B | 143.46B | 129.63B | 163.03B | Total Assets |
928.50B | 922.77B | 838.22B | 789.65B | 656.54B | Total Debt |
271.02B | 298.54B | 237.74B | 250.42B | 165.59B | Net Debt |
102.43B | 124.60B | 108.49B | 134.81B | 12.41B | Total Liabilities |
490.54B | 519.75B | 435.82B | 447.17B | 323.33B | Stockholders Equity |
434.04B | 399.53B | 399.01B | 339.36B | 330.50B |
Cash Flow | Free Cash Flow | |||
123.54B | 92.48B | 64.20B | 55.16B | 55.56B | Operating Cash Flow |
130.20B | 142.28B | 118.90B | 98.14B | 84.59B | Investing Cash Flow |
-47.59B | -53.42B | -61.19B | -130.55B | -20.52B | Financing Cash Flow |
-87.31B | -47.58B | -44.92B | -8.00B | -13.18B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $3.23T | 34.74 | 22.20% | 1.06% | 3.84% | 19.26% | |
62 Neutral | $11.80B | 10.31 | -7.45% | 2.91% | 7.43% | -7.78% | |
$42.78B | 29.77 | 11.70% | 0.79% | ― | ― | ||
$36.01B | 30.56 | 8.97% | 0.70% | ― | ― | ||
$38.55B | 37.24 | 7.94% | 0.67% | ― | ― | ||
74 Outperform | ¥1.07T | 21.36 | 1.52% | 4.13% | 5.65% | ||
74 Outperform | ¥1.31T | 29.10 | 1.69% | 24.10% | 11.27% |
Nomura Research Institute, Ltd. has announced its decision to amend its Articles of Incorporation to transition from a ‘Company with an Audit & Supervisory Board’ to a ‘Company with an Audit & Supervisory Committee.’ This change, set to be approved at the upcoming Ordinary General Meeting of Shareholders in June 2025, aims to streamline corporate governance by establishing new provisions for the committee and delegating decision-making powers to board members. This strategic move is expected to enhance operational efficiency and strengthen oversight, potentially impacting stakeholders by improving transparency and accountability within the company.
The most recent analyst rating on (JP:4307) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Nomura Research Institute stock, see the JP:4307 Stock Forecast page.
Nomura Research Institute announced a dividend payment from retained earnings, with a year-end dividend of ¥34 per share for the fiscal year ending March 31, 2025, reflecting an increase from the previous year. This decision aligns with NRI’s policy to provide stable dividends while aiming to improve capital efficiency and shareholder returns, with plans to increase the consolidated dividend payout ratio to 40% by March 2026.
The most recent analyst rating on (JP:4307) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Nomura Research Institute stock, see the JP:4307 Stock Forecast page.
Nomura Research Institute reported a strong financial performance for the fiscal year ended March 31, 2025, with notable increases in revenue and profit. The company achieved a 3.8% increase in revenue and a 17.7% rise in profit attributable to owners, reflecting robust operational efficiency and strategic growth. The company also announced an increase in dividends, indicating confidence in its financial stability and commitment to shareholder returns.